Ardigen’s Strategic Leap: Livia Legg to Spearhead Growth as New CCO

Facebook
Pinterest
Twitter
LinkedIn

Ardigen Welcomes Livia Legg as New Chief Commercial Officer

Ardigen, a forefront AI Contract Research Organization (AI CRO), is proud to announce the strategic appointment of Livia Legg as the new Chief Commercial Officer. This significant move is set to bolster the company’s ambitious growth trajectory. Legg, who brings over two decades of industry experience, will be joining the Ardigen Board of Management with the aim of enhancing sales strategies and accelerating the company’s expansion in the biotech and pharmaceutical sectors.

Legg’s impressive background includes key positions at Shanghai ChemPartner and QPS, LLC, equipping her with extensive expertise in business development and commercial operations. Her appointment underscores Ardigen’s dedication to strengthening its leadership team and cementing its status as a pioneer in the application of AI for pharmaceutical development.

Janusz Homa, CEO of Ardigen, expressed his enthusiasm for Legg’s joining, highlighting her strategic insight as vital for the company’s future endeavors. Legg herself is excited about the opportunity to contribute to a company that is at the intersection of AI innovation and pharmaceutical and biotechnology partnerships, aiming to drive growth and achieve transformative outcomes.

Legg’s role at Ardigen is in line with the company’s mission to enhance the success rate in drug development by leveraging AI platforms and delivering scientific insights that add substantial value to clients and have the potential to revolutionize the industry. This appointment marks a key phase of growth for Ardigen, indicating a stronger market presence and alignment with the ongoing trend of integrating AI in life sciences.